Literature DB >> 18829920

Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis.

Charles J Glueck1, Richard A Freiberg, Swapna Boppana, Ping Wang.   

Abstract

BACKGROUND: We examined the hypothesis that thrombophilia, hypofibrinolysis, and the endothelial nitric oxide synthase (eNOS) T-786C polymorphism are common, potentially treatable, and similar pathophysiologic causes of multifocal (three sites or more) and unifocal (single-site) osteonecrosis.
METHODS: We prospectively evaluated twenty-six consecutively referred adults with multifocal osteonecrosis, who included thirteen with idiopathic multifocal osteonecrosis and thirteen with secondary multifocal osteonecrosis (resulting from steroid therapy in ten and alcoholism in three). We compared these patients with race, sex, and age-matched normal control subjects and with patients with idiopathic unifocal and secondary unifocal osteonecrosis, respectively. Using polymerase chain reaction and serologic measures, we studied thrombophilic and hypofibrinolytic mutations and the eNOS T-786C polymorphism.
RESULTS: The total number of polymerase chain reaction and serologic thrombophilic-hypofibrinolytic abnormalities and the eNOS T-786C polymorphism did not differ between patients with idiopathic (p > 0.5) or secondary (p > 0.5) multifocal and unifocal osteonecrosis. The frequency of low free protein-S levels (<66%) in patients with secondary multifocal osteonecrosis (four of eleven patients) was higher than that in the control subjects (one of fifty-nine) (risk ratio = 21.5; 95% confidence interval, 2.6 to 174; p = 0.0016, Benjamini-Hochberg adjusted p [Bp] = 0.004). Factor-V Leiden heterozygosity was present in two of thirteen patients with secondary multifocal osteonecrosis compared with none of sixty-four control subjects (p = 0.027, Bp = 0.008). For eleven patients with secondary multifocal osteonecrosis, the eNOS T-786C polymorphism was present in nine of twenty-two alleles compared with eight of forty-four alleles in twenty-two normal control subjects (risk ratio = 2.3; 95% confidence interval, 1.0 to 5.0; p = 0.047, Bp = 0.016). The frequency of homocystinemia (>13.5 mumol/L) was higher in patients with idiopathic multifocal osteonecrosis (two of thirteen patients) than in normal controls (none of fifty-one) (p = 0.039, Bp = 0.004). A high level of factor VIII (>150%) was seen in four of eight patients with idiopathic multifocal osteonecrosis and in seven of forty-eight normal controls (risk ratio = 3.4; 95% confidence interval, 1.3 to 9.1; p = 0.04, Bp = 0.008). The eNOS T-786C mutant allele was present in seven of twelve alleles in the six patients with idiopathic multifocal osteonecrosis who were tested, compared with twenty-five of 108 alleles in fifty-four control subjects (risk ratio = 2.5; 95% confidence interval, 1.4 to 4.5; p = 0.015, Bp = 0.008).
CONCLUSIONS: Limited by the small numbers of patients with multifocal osteonecrosis, this exploratory study suggested that thrombophilia was associated with both idiopathic multifocal osteonecrosis and secondary multifocal osteonecrosis, as was the eNOS T-786C polymorphism. Multifocal and unifocal osteonecrosis are similarly associated with thrombophilia, hypofibrinolysis, and the eNOS T-786C polymorphism, which are potentially treatable pathophysiologic conditions, requiring further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829920     DOI: 10.2106/JBJS.G.00616

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  20 in total

1.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

2.  Pathophysiology and risk factors for osteonecrosis.

Authors:  Kalpit N Shah; Jennifer Racine; Lynne C Jones; Roy K Aaron
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 3.  Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis.

Authors:  Christian Powell; Christopher Chang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

4.  Bilateral Legg-Calve-Perthes Disease and Kienbock's Disease in a Child With Factor V Leiden Thrombophilia: A Case Report.

Authors:  Heather L Baltzer; Scott Riester; Steven L Moran
Journal:  Hand (N Y)       Date:  2016-02-26

5.  The relationship between genetic polymorphisms in apolipoprotein E (ApoE) gene and osteonecrosis of the femoral head induced by steroid in Chinese Han population.

Authors:  Lin Yuan; Wei Li; Xianquan Wang; Guang Yang; Haiyang Yu; Shui Sun
Journal:  Genes Genomics       Date:  2017-11-01       Impact factor: 1.839

Review 6.  Association of eNOS polymorphisms with susceptibility to osteonecrosis of the femur head : A meta-analysis.

Authors:  G G Song; Y H Lee
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

7.  Meta-analysis of Factor V Leiden G1691A polymorphism and osteonecrosis of femoral head susceptibility.

Authors:  Xifu Shang; Zhengliang Luo; Xu Li; Fei Hu; Qichun Zhao; Wenzhi Zhang
Journal:  Biomed Rep       Date:  2013-04-09

8.  Association of eNOS 27-bp VNTR, 894G>T and 786T>C polymorphisms with susceptibility to Legg-Calve-Perthes Disease in Iranian children.

Authors:  Mohammad Reza Azarpira; Mohammad Mahdi Ghilian; Mohammad Reza Sobhan; Masoud Mahdinezhad-Yazdi; Kazem Aghili; Hossein Ahrar; Hossein Neamatzadeh
Journal:  J Orthop       Date:  2019-02-26

9.  Expanding diagnostic approach in patients with osteonecrosis.

Authors:  José A Gómez-Puerta; Pilar Peris
Journal:  Arthritis Res Ther       Date:  2021-05-25       Impact factor: 5.156

Review 10.  Osteonecrosis of the Femoral Head: an Updated Review of ARCO on Pathogenesis, Staging and Treatment.

Authors:  Jeremy T Hines; Woo Lam Jo; Quanjun Cui; Michael A Mont; Kyung Hoi Koo; Edward Y Cheng; Stuart B Goodman; Yong Chan Ha; Phillippe Hernigou; Lynne C Jones; Shin Yoon Kim; Takashi Sakai; Nobuhiko Sugano; Takuaki Yamamoto; Mel S Lee; Dewei Zhao; Wolf Drescher; Tae Young Kim; Young Kyun Lee; Byung Ho Yoon; Seung Hoon Baek; Wataru Ando; Hong Seok Kim; Jung Wee Park
Journal:  J Korean Med Sci       Date:  2021-06-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.